The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

CCRIS 339     N-(4-ethoxyphenyl)-N-hydroxy- ethanamide

Synonyms: NSC-229647, AC1L1HNK, LS-13108, NSC229647, AKOS006272871, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of CCRIS 339

 

High impact information on CCRIS 339

 

Biological context of CCRIS 339

 

Anatomical context of CCRIS 339

 

Analytical, diagnostic and therapeutic context of CCRIS 339

References

  1. Mechanism of N-hydroxyacetylarylamine mutagenicity in the Salmonella test system: metabolic activation of N-hydroxyphenacetin by liver and kidney fractions from rat, mouse, hamster, and man. Wirth, P.J., Dybing, E., von Bahr, C., Thorgeirsson, S.S. Mol. Pharmacol. (1980) [Pubmed]
  2. N-Hydroxy-N-arylacetamides. I. Toxicity of certain polycyclic and monocyclic N-hydroxy-N-arylacetamides in rats. Fischbach, T., Hertle, H., Kiese, M., Lenk, W., Sterzl, H., Meister, P. Arch. Toxicol. (1984) [Pubmed]
  3. Inhibition of DNA, RNA and protein synthesis and chromatin alteration by N-hydroxyphenacetin. Hayward, N.K., Lavin, M.F. Xenobiotica (1987) [Pubmed]
  4. Metabolic activation and genotoxicity of N-hydroxy-2-acetylaminofluorene and N-hydroxyphenacetin derivatives in Reuber (H4-II-E) hepatoma cells. Glowinski, I.B., Sanderson, N.D., Hayashi, S., Thorgeirsson, S.S. Cancer Res. (1984) [Pubmed]
  5. Species-specific activation of phenacetin into bacterial mutagens by hamster liver enzymes and identification of N-hydroxyphenacetin O-glucuronide as a promutagen in the urine. Camus, A.M., Friesen, M., Croisy, A., Bartsch, H. Cancer Res. (1982) [Pubmed]
  6. Activation of N-hydroxyphenacetin to mutagenic and nucleic acid-binding metabolites by acyltransfer, deacylation, and sulfate conjugation. Vaught, J.B., McGarvey, P.B., Lee, M.S., Garner, C.D., Wang, C.Y., Linsmaier-Bednar, E.M., King, C.M. Cancer Res. (1981) [Pubmed]
  7. N-hydroxyphenacetin, a new urinary metabolite of phenacetin in the rat. McLean, S., Davies, N.W., Watson, H., Favretto, W.A., Bignall, J.C. Drug Metab. Dispos. (1981) [Pubmed]
  8. Metabolism of phenacetin and N-hydroxyphenacetin in isolated rat hepatocytes. McLean, S. Naunyn Schmiedebergs Arch. Pharmacol. (1978) [Pubmed]
  9. N-Hydroxylation of phenacetin by hamster liver microsomes. Hinson, J.A., Mitchell, J.R. Drug Metab. Dispos. (1976) [Pubmed]
  10. The metabolism of N-hydroxyphenacetin in vitro and in vivo. Fischbach, T., Lenk, W. Xenobiotica (1985) [Pubmed]
  11. Mass spectrometric determination of N-hydroxyphenacetin in urine using multiple metastable peak monitoring following thin-layer chromatography. Davies, N.W., Veronese, M.E., McLean, S. J. Chromatogr. (1984) [Pubmed]
 
WikiGenes - Universities